AR064108A1 - Tratamiento de ansiedad con eszopiclona - Google Patents

Tratamiento de ansiedad con eszopiclona

Info

Publication number
AR064108A1
AR064108A1 ARP070105392A ARP070105392A AR064108A1 AR 064108 A1 AR064108 A1 AR 064108A1 AR P070105392 A ARP070105392 A AR P070105392A AR P070105392 A ARP070105392 A AR P070105392A AR 064108 A1 AR064108 A1 AR 064108A1
Authority
AR
Argentina
Prior art keywords
eszopiclone
anxiety treatment
anxiety
treatment
anxiolytic
Prior art date
Application number
ARP070105392A
Other languages
English (en)
Original Assignee
Sepracor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sepracor Inc filed Critical Sepracor Inc
Publication of AR064108A1 publication Critical patent/AR064108A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma farmacéutica unitaria con una dosificacion ansiolítica de eszopiclona. Método para el tratamiento o la profilaxis de la ansiedad usando una dosificacion subsedante de eszopiclona.
ARP070105392A 2006-12-01 2007-12-03 Tratamiento de ansiedad con eszopiclona AR064108A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86827906P 2006-12-01 2006-12-01

Publications (1)

Publication Number Publication Date
AR064108A1 true AR064108A1 (es) 2009-03-11

Family

ID=39322503

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105392A AR064108A1 (es) 2006-12-01 2007-12-03 Tratamiento de ansiedad con eszopiclona

Country Status (6)

Country Link
US (1) US20080175903A1 (es)
EP (1) EP2101776A2 (es)
AR (1) AR064108A1 (es)
CA (1) CA2670593A1 (es)
TW (1) TW200831097A (es)
WO (1) WO2008070000A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1691811E (pt) * 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
CA2677470A1 (en) 2004-04-05 2005-10-20 Sepracor Inc. Methods of treatment using eszopiclone
MX2008000250A (es) 2005-07-06 2008-03-19 Sepracor Inc Combinaciones de eszopiclona y trans-4-(3,4-diclorofenil)-1,2,3,4- tetrahidro-n-metil-1-naftalenamina o trans 4-(3,4-diclorofenil)-1, 2,3,4-tetrahidro-1-naftalenamina y metodos de tratamiento de menopausia y trastornos del estado de animo, ansiedad y
US20080305171A1 (en) * 2007-06-07 2008-12-11 Kristin Anne Arnold Pyrrolopyrazine, formulations, methods of manufacture, and methods of use there
US8269005B2 (en) * 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-Oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198277B2 (en) 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. L-malate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8268832B2 (en) 2007-12-19 2012-09-18 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-Pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8212036B2 (en) 2007-12-19 2012-07-03 Sunovion Pharmaceuticals Inc. Maleate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
US8198278B2 (en) * 2007-12-19 2012-06-12 Sunovion Pharmaceuticals Inc. Besylate salts of 6-(5-chloro-2-pyridyl)-5-[(4-methyl-1-piperazinyl)carbonyloxy]-7-oxo-6,7-dihydro-5H-pyrrolo[3,4-b]pyrazine
WO2012075117A2 (en) * 2010-12-01 2012-06-07 Ablitech, Inc. Small molecule-polymer conjugates and methods of making same
US11648207B1 (en) * 2021-12-15 2023-05-16 Intas Pharmaceuticals Ltd. Extended release pharmaceutical composition of Clozapine

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786357A (en) * 1991-12-02 1998-07-28 Sepracor Inc. Methods and compositions for treating sleep disorders, convulsive seizures and other disorders using optically pure (+) zopiclone
US8309104B2 (en) * 2006-03-02 2012-11-13 Watson Pharmaceuticals, Inc. Oral controlled release formulation for sedative and hypnotic agents

Also Published As

Publication number Publication date
CA2670593A1 (en) 2008-06-12
EP2101776A2 (en) 2009-09-23
WO2008070000A2 (en) 2008-06-12
US20080175903A1 (en) 2008-07-24
TW200831097A (en) 2008-08-01
WO2008070000A3 (en) 2008-08-21

Similar Documents

Publication Publication Date Title
AR064108A1 (es) Tratamiento de ansiedad con eszopiclona
CL2008000822A1 (es) Metodo para el tratamiento de la obesidad usando un inhibidor sglt2.
CL2016002144A1 (es) Inhibidores de la jak1 para el tratamiento de síndromes mielodisplásicos.
CO6531429A2 (es) Inhibidores de la tirosina quinasa de bruton
CL2007001670A1 (es) Uso de compuestos derivados de amina para el tratamiento de un trastorno mediado por citoquinas.
EA201171367A1 (ru) Винилиндазолильные соединения
UY34165A (es) ?compuestos aldh-2 mitocondriales humanos para el tratamiento de la adicción?.
CL2011000191A1 (es) Compuestos derivados de pirimidina fusionada sustituida,inhibidores de mtor; composicion farmaceutica que lo comprende; y uso en el tratamiento del cancer.
CL2009000545A1 (es) Uso de un antagonista de c-met y un antagonista de her para el tratamiento de cancer.
UY34037A (es) Nuevo compuesto útil para el tratamiento de enfermedades degenerativas e inflamatorias.
CL2011000101A1 (es) Compuestos derivados de piridazina sustituida; inhibidores de la señalizacion hedgehog y smo; composicion farmaceutica; y uso para el tratamiento de trastornos o sindromes asociados con enfermedades hiperproliferativas.
ECSP077360A (es) Compuestos sulfonamida
EA201300810A1 (ru) Противораковая терапия с использованием двойных ингибиторов киназ аврора/мек
CL2008002042A1 (es) Compuestos derivados de heterociclos nitrogenados enlazados; y su uso en el tratamiento de la diabetes y desordenes metabolicos.
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
BR112012013260A2 (pt) dispositivo usado para o tratamento de rinite através de iluminação bioestimulativa
EA201170252A1 (ru) Амидофеноксиндазолы в качестве ингибиторов c-мет
AR080872A1 (es) Biomarcadores para inhibidores de mdm2 para su uso en el tratamiento de enfermedad
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
CL2008001038A1 (es) Uso de una composicion que comprende un antagonosta h1, y un compuesto anti-tnf alfa para tratar conjuntivitis alegica o rinitis alergiva en un sujeto humano
UY30846A1 (es) Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
UY31136A1 (es) Oxazolidinonas sustituidas y su uso
BRPI0911577A2 (pt) derivados espiro-indol para o tratamento de doenças parasíticas.
ECSP11011021A (es) Antagonistas de la via hedgehog de ftalazina disustituida
CY1110658T1 (el) Χρηση του καρραγηνου για τη θεραπεια μολυνσεων απο ρινοϊο

Legal Events

Date Code Title Description
FB Suspension of granting procedure